col0,col1,col2,col3,col4,col5,col6,col7
adalimumab,Humira,immunologic factor,Adalimumab,2.9,pyoderma gangrenosum,US pregnancy categoryÂ B,biopharmaceutical
denosumab,Prolia,bone density conservation agents,Denosumab,0.33,bone fracture,Australian pregnancy category D,chemical compound
Daclizumab,Zenapax,immunosuppressive drug,Daclizumab,0.35,multiple sclerosis,US pregnancy category C,chemical compound
Siltuximab,Sylvant,antineoplastic,Siltuximab,37,Castleman's disease,US pregnancy category C,biopharmaceutical
